Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TOBIpodhaler (tobramycin)
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
TOBI Podhaler is an inhaled dry powder formulation of the aminoglycoside antibiotic tobramycin, specifically developed for the management of *Pseudomonas aeruginosa* airway colonization in patients with cystic fibrosis. Developed by Novartis and currently marketed by Viatris, the product utilizes PulmoSphere technology to create light, porous particles delivered via a portable, breath-actuated dry powder inhaler (the Podhaler). This delivery system was designed to improve patient convenience and adherence by significantly reducing administration time compared to traditional nebulized tobramycin inhalation solutions (TIS), as it requires no power source, refrigeration, or complex maintenance. Tobramycin exerts its antibacterial effect by irreversibly binding to the 30S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis and leading to bacterial cell death.
- Brand names
- TOBI PodhalerTOBI
- Other names
- Tobramycin Inhalation Powder
02
Targets
Bacterial RibosomeOM/IM (Bacterial outer and inner membranes)MT-RNR1 (Human mitochondrial 12S ribosomal RNA)
Beyond the preview
Go deeper on TOBIpodhaler (tobramycin).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TOBIpodhaler (tobramycin).